Company profile
Sandoz Group AG
SDZ · SIX (Sandoz's official annual report identifies Sandoz Group AG as an independent public company listed on SIX under SDZ; CT.gov and GLEIF evidence establish the reviewed sponsor identity. Sources: https://clinicaltrials.gov/study/NCT04864834 ; https://api.gleif.org/api/v1/lei-records/5493000JWK6XWFEUD320 Entity resolved by asset-pipeline-v2.)
Public Market Listing
Live quotes, historical charts, and market capitalization for Sandoz Group AG are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
Aflibercept(Eylea) | Approved | VEGF-A · VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Protein / enzyme therapeutic | Age-Related Macular Degeneration |
Ranibizumab(Lucentis) | Approved | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration |
Tyruko (natalizumab-sztn)(Tyruko) | Approved | α4 integrinMonoclonal antibody | Multiple Sclerosis |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.